1 active not recruiting, 1 completed, 1 withdrawn. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Multiple Indications Cancer: new trials by email Literature Review of Multiple Indications Cancer trials Research Report on Multiple Indications Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG Oral FDG scan - Multiple Cancers, Multiple Indications Cancer | Not applicable | Active not recruiting | British Columbia Cancer Agency | 27 | 2026-02-10 | 2026-09-29 |
| Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico Non-Interventional - Multiple Indications Cancer | Withdrawn | Bristol-Myers Squibb | 2017-07-17 | 2022-05-27 | ||
| Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib Dasatinib - Multiple Indications Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 17 | 2015-07-31 | 2023-05-06 |
Dasatinib (1)
Bristol-Myers Squibb (2) · British Columbia Cancer Agency (1)
Canada (1) · France (1) · Mexico (1) · Poland (1)